Search

Displaying results 1091 - 1100 of 1804 in total
  1. Target

    Leukocyte immunoglobulin-like receptor subfamily A member 4

    go.drugbank.com/bio_entities/BE0013620
    TargetHumans

    Functions coreceptor to limit the innate immune responses to viral infections; signaling occurs via FCER1G (PubMed:16735691, PubMed:19564354).

    Polypeptides: Leukocyte immunoglobulin-like receptor subfamily A member 4
  2. Target

    Peroxisome proliferator-activated receptor gamma coactivator 1-alpha

    go.drugbank.com/bio_entities/BE0020703
    TargetHumans

    Greatly increases the transcriptional activity of PPARG and thyroid hormone receptor on the uncoupling protein promoter (PubMed:10713165, PubMed:20005308, PubMed:21376232).

    Polypeptides: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha
  3. Drug

    Racemethionine

    go.drugbank.com/drugs/DB13972
    Approved

    A preparation of methionine that includes a mixture of D-methionine and L-methionine isomers.

    Mixtures: Vita-vim - Tab, Vita Balance 2000
  4. Drug

    Efgartigimod alfa

    go.drugbank.com/drugs/DB15270
    ApprovedInvestigational

    [L39496] IgG antibodies, including the autoantibodies responsible for MG symptoms, can be 'recycled', a process that significantly extends their half-life by evading lysosomal degradation via binding with … [A243759,A243784] Efgartigimod alfa is a first-in-class[L39501] antagonist of the neonatal Fc receptor (FcRn) used in the treatment of MG.

    Categories: Neonatal Fc Receptor Blocker
  5. Drug

    Lucanthone

    go.drugbank.com/drugs/DB04967
    Investigational

    One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.

  6. Drug

    Afizagabar

    go.drugbank.com/drugs/DB21439
    Investigational

    Afizagabar is under investigation in clinical trial NCT02877615 (Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event).

    Categories: GABA-A Receptor Antagonists
  7. Drug

    Diflunisal

    go.drugbank.com/drugs/DB00861
    Approved

    Though its mechanism of action has not been clearly established, most of its actions appear to be associated with inhibition of prostaglandin synthesis via the arachidonic acid pathway.

  8. Drug

    Ulipristal

    go.drugbank.com/drugs/DB08867
    ApprovedInvestigational

    A recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily … It also binds to glucocorticoid receptor, however compared to mifepristone (a progesterone receptor antagonist), ulipristal is more tolerable and has lower glucocorticoid activity and better binding affinity

    Categories: Progesterone Receptor Modulators, Selective Progesterone Receptor Modulators
  9. Drug

    Anthralin

    go.drugbank.com/drugs/DB11157
    Approved

    Anthralin (1,8‐dihydroxy‐9anthrone, dithranol) is an older anti-psoriatic agent that was first synthesized as a derivative of chrysarobin, obtained from the araroba tree in Brazil over 100 years ago. Adverse effects of anthralin include ...

  10. Indication

    Type II Hyperlipidaemia

    go.drugbank.com/conditions/DBCOND0040511
    Drugs: Niacin
    Synonyms: LDL receptor disorder, LDL - Low density lipoprotein receptor disorder